Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D
Authors:
Open Access
- 1 August 2014
- Vol. 5 (4) , E84-E87-E87
Abstract
Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin DKeywords
This publication has 11 references indexed in Scilit:
- Unusual Complication of a Pancreatic Neuroendocrine Tumor Presenting with Malignant HypercalcemiaThe Journal of Clinical Endocrinology & Metabolism, 2012
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 2010
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalAnnals of Oncology, 2008
- Hypercalcemia Associated with CancerNew England Journal of Medicine, 2005
- Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failurePostgraduate Medical Journal, 2002
- Parathyroid hormone‐related peptide in pancreatic neuroendocrine tumours associated with hypercalcaemiaHPB, 2001
- Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas.1993
- Immunochemical Characterization of Circulating Parathyroid Hormone–Related Protein in Patients with Humoral Hypercalcemia of CancerNew England Journal of Medicine, 1990